Literature DB >> 34540705

The Efficacy and Short- and Long-Term Side Effects of Radioactive Iodine Treatment in Pediatric Graves' Disease: A Systematic Review.

Sarah L Lutterman1, Nitash Zwaveling-Soonawala1, Hein J Verberne2, Frederik A Verburg3, A S Paul van Trotsenburg1, Christiaan F Mooij1.   

Abstract

BACKGROUND: Graves's disease (GD) is the most common cause of hyperthyroidism. Maximal 30% of pediatric GD patients achieve remission with antithyroid drugs. The majority of patients therefore require definitive treatment. Both thyroidectomy and radioactive iodine (RAI) are often used as definitive treatment for GD. However, data on efficacy and short- and long-term side effects of RAI treatment for pediatric GD are relatively scarce.
METHODS: A systematic review of the literature (PubMed and Embase) was performed to identify studies reporting the efficacy or short- and long-term side effects of RAI treatment in pediatric GD.
RESULTS: Twenty-three studies evaluating 1,283 children and adolescents treated with RAI for GD were included. The treatment goal of RAI treatment changed over time, from trying to achieve euthyroidism in the past to aiming at complete thyroid destruction and subsequent hypothyroidism in the last 3 decades. The reported efficacy of a first RAI treatment when aiming at hypothyroidism ranged from 42.8 to 97.5%, depending on the activity administered. The efficacy seems to increase with higher RAI activities. When aiming at hypothyroidism, both short- and long-term side effects of treatment are very rare. Long-term side effects were mainly seen in patients in whom treatment aimed at achieving euthyroidism.
CONCLUSION: RAI is a safe definitive treatment option for pediatric GD when aiming at complete thyroid destruction. When aiming at hypothyroidism, the efficacy of treatment seems to increase with a higher RAI activity. Prospective studies are needed to determine the optimal RAI dosing regimen in pediatric GD.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Graves' disease; Pediatric Graves' disease; Radioactive iodine; Side effects

Year:  2021        PMID: 34540705      PMCID: PMC8406249          DOI: 10.1159/000517174

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  43 in total

1.  Comparative Effectiveness of Treatment Choices for Graves' Hyperthyroidism: A Historical Cohort Study.

Authors:  Vishnu Sundaresh; Juan P Brito; Prabin Thapa; Rebecca S Bahn; Marius N Stan
Journal:  Thyroid       Date:  2017-02-06       Impact factor: 6.568

2.  Normal volume of the thyroid gland in children.

Authors:  D Ueda
Journal:  J Clin Ultrasound       Date:  1990 Jul-Aug       Impact factor: 0.910

3.  EANM procedure guidelines for therapy of benign thyroid disease.

Authors:  Marcel P M Stokkel; Daria Handkiewicz Junak; Michael Lassmann; Markus Dietlein; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

4.  Influence of iodine-131 dose on the outcome of hyperthyroidism in children.

Authors:  Scott A Rivkees; Eugene A Cornelius
Journal:  Pediatrics       Date:  2003-04       Impact factor: 7.124

5.  Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period.

Authors:  Paul B Kaplowitz; Jiji Jiang; Priya Vaidyanathan
Journal:  J Pediatr Endocrinol Metab       Date:  2020-03-26       Impact factor: 1.634

6.  [Efficacy of treatment with I(131) in paediatric Graves disease].

Authors:  P Enes Romero; M Martín-Frías; M de Jesús; C Caballero Loscos; M Alonso Blanco; R Barrio Castellanos
Journal:  An Pediatr (Barc)       Date:  2013-06-21       Impact factor: 1.500

7.  Comparative analysis of radioactive iodine versus thyroidectomy for definitive treatment of Graves disease.

Authors:  Vincent T Wu; Allison W Lorenzen; Anna C Beck; Vincent J Reid; Sonia L Sugg; James R Howe; Janet H Pollard; Geeta Lal; Ronald J Weigel
Journal:  Surgery       Date:  2016-11-15       Impact factor: 3.982

8.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02

9.  Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children.

Authors:  Todd D Nebesio; Aslam R Siddiqui; Ora H Pescovitz; Erica A Eugster
Journal:  J Pediatr       Date:  2002-07       Impact factor: 4.406

10.  Differentiated thyroid carcinoma in children: Clinical characteristics and long-term follow-up.

Authors:  Muge Tamam; Ercan Uyanik; Nurcan Edís; Mehmet Mulazimoglu; Tevfik Ozpacaci
Journal:  World J Nucl Med       Date:  2019-11-06
View more
  1 in total

1.  2022 European Thyroid Association Guideline for the management of pediatric Graves' disease.

Authors:  Christiaan F Mooij; Timothy D Cheetham; Frederik A Verburg; Anja Eckstein; Simon H Pearce; Juliane Léger; A S Paul van Trotsenburg
Journal:  Eur Thyroid J       Date:  2022-01-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.